Anavex Life Sciences Corp (AVXL)

[frrol]

Yes and the company is going to be accused of "data mining" in the Part B by the bears. That is typical and OK. As long as we use robust analytics in a large Phase 2/3, the bearish criticism is irrelevant. The "donepezil synergy" assertion last year and "no grouping" assertion this July lost the company some credibility in the market. They will survive it if the 52-week results show efficacy in the sub-pops. Objective results are what will rule the day.